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ABSTRACT
siRNAs are a new class of therapeutic modalities
with promising clinical efficacy that requires modi-
fication or formulation for delivery to the tissue and
cell of interest. Conjugation of siRNAs to lipophilic
groups supports efficient cellular uptake by a mecha-
nism that is not well characterized. Here we study the
mechanism of internalization of asymmetric, chem-
ically stabilized, cholesterol-modified siRNAs (sd-
rxRNAs®) that efficiently enter cells and tissues
without the need for formulation. We demonstrate
that uptake is rapid with significant membrane as-
sociation within minutes of exposure followed by the
formation of vesicular structures and internalization.
Furthermore, sd-rxRNAs are internalized by a spe-
cific class of early endosomes and show preferential
association with epidermal growth factor (EGF) but
not transferrin (Tf) trafficking pathways as shown by
live cell TIRF and structured illumination microscopy
(SIM). In fixed cells, we observe ∼25% of sd-rxRNA
co-localizing with EGF and <5% with Tf, which is
indicative of selective endosomal sorting. Likewise,
preferential sd-rxRNA co-localization was demon-
strated with EEA1 but not RBSN-containing endo-
somes, consistent with preferential EGF-like traffick-
ing through EEA1-containing endosomes. sd-rxRNA
cellular uptake is a two-step process, with rapid
membrane association followed by internalization
through a selective, saturable subset of the endo-
cytic process. However, the mechanistic role of EEA1
is not yet known. This method of visualization can be
used to better understand the kinetics and mecha-
nisms of hydrophobic siRNA cellular uptake and will
assist in further optimization of these types of com-
pounds for therapeutic intervention.
INTRODUCTION
A broad range of human diseases, including cancer, infec-
tion and neurodegeneration, can be treated via the silenc-
ing of specific genes using small oligonucleotides. Oligonu-
cleotide therapeutics (ONTs) are a new class of drugs that
are distinguished by targeting DNA or RNA directly, thus
preventing expression of the protein responsible for the
disease phenotype (1–3). Advantages of ONTs over con-
ventional drugs include ease of drug design based solely
on base-pairing rules, the ability to access targets previ-
ously considered ‘undruggable’, and their promise of un-
precedented specificity, potency, and duration of effect
(4). In addition, the pharmacokinetics, pharmacodynam-
ics, and safety of ONTs are mostly defined by chemical
modifications/formulation (5); these characteristics tend
to be very similar between compounds targeting different
genes, enabling multi-gene silencing and simple develop-
ment of drugs targeting specific tissues (6). Significant ef-
fort in the last decade resulted in the development of several
types of both chemically-modified and formulated ONTs
with clear clinical efficacy (7). Thus, ONTs represent a
new and potentially transformative therapeutic paradigm.
Nonetheless, their clinical utility has been mostly limited to
hepatocyte delivery (8) and local administration (9).
siRNAs comprise one of the major classes of ONTs.
These small double-stranded oligonucleotides consist of
guide (antisense) and passenger (sense) strands and utilize
the RNA interference (RNAi) pathway (10). Upon cellu-
lar uptake, the guide strand is loaded into an RNA induced
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silencing complex (RISC) capable of cleaving its comple-
mentary target RNA. The number of loaded RISCs per cell
sufficient to induce efficient and long-term gene silencing
is estimated at ∼25-100 in vitro (11) and ∼400 in vivo (12).
Usually 10–100 ng siRNA/g of tissue is enough to gener-
ate sufficient active RISCs to induce silencing (12). Loaded
RISCs have week-long stability, resulting in prolonged gene
silencing (3-6 weeks) from a single administration (7).
Oligonucleotides are charged non-biologically stable
molecules which need to be modified or formulated to en-
able cellular delivery. Furthermore, their efficacy is defined
by both the ability to be delivered to cells and tissues as well
as biological availability inside the cell, with the vast ma-
jority of internalized compounds being trapped unproduc-
tively in lysosomes and other ‘oligonucleotide sinks’ (13–
15). Conjugation of stabilized siRNAs to bioactive con-
jugates has been shown to promote activity both in vivo
and in vitro. Despite years of exploration, only a limited
number of formulations and conjugates have progressed
to the clinic: lipid nanoparticles (LNPs) (16,17), dynamic
polyconjugates (18), dextrins (19), N-acetylgalactosamine
(GalNAc) (8) and cholesterol (9). The most clinically ad-
vanced delivery platform is GalNAc-conjugated siRNA
(GalNAc-siRNA) with several compounds showing robust
clinically efficacy (20–22). Trivalent GalNAc ligands fa-
cilitate the uptake of GalNAc-siRNAs into hepatocytes
through an interaction with asialoglycoprotein receptors
(ASGPRs) overexpressed on the surface of hepatocytes.
While promising, both GalNAc-siRNAs and LNPs are
mostly limited to liver-associated delivery and diseases. Al-
ternatively, lipophilic conjugates promote efficient cellular
internalization independently of cell type, with one com-
pound being currently evaluated for the treatment of hy-
pertrophic scarring following local skin administration (23).
While the mechanism of GalNAc-siRNAs (24) and LNP
(13,25–27) formulated siRNA uptake is relatively well char-
acterized, only limited data exists regarding the internal-
ization of lipophilic siRNAs (28,29). Wolfrum et al. (30)
have demonstrated that a fraction of cholesterol modi-
fied siRNAs binds to different lipoproteins in blood and
LDL/HDL complexes associate with cells and tissues,
which has also been repeated with other hydrophobically
modified oligonucleotides (31,32). It is unclear if the mech-
anism of cellular intrnalization in vivo and in vitro is sim-
ilar since in vitro, serum and LDL/HDL strongly inhibit
functional efficacy of cholesterol modified siRNAs, with
the best efficacy observed in serum-free media (Supplemen-
tary Figure S1). Here, we decided to systematically visual-
ize the internalization of the lipophilic siRNAs using small,
asymmetric, hydrophobically modified siRNAs called sd-
rxRNAs (9,33).
We show that sd-rxRNAs are quickly internalized
through the formation of vesicular structures, indicative of
endocytosis. Given that inefficient delivery of siRNA to the
site of action inside the cell remains one of the major limita-
tions of RNAi-based drugs, dissecting the precise intracel-
lular trafficking mechanisms of conjugated siRNAs could
elucidate the functional relevance of these pathways. Fur-
thermore, recent results determined that early endosomes
are heterogeneous, displaying different sizes, motilities, and
phosphoinositide effector complements (34–36). These en-
dosomes may be specialized for the trafficking of differ-
ent cargos, as receptors for transferrin (Tf) and epidermal
growth factor (EGF) are found in different subsets of endo-
somes almost immediately after internalization (37). More-
over, the genetic networks involved in the early traffick-
ing of the Tf and EGF receptors differ substantially from
each other (38). Directly distinguishing specific internaliza-
tion pathways requires high temporal and spatial resolu-
tion to visualize the movement of ligands from the outside
to the inside of the cell, and amongst distinct early endo-
cytic structures. We used a recently developed microscopy
platform that combines total internal reflection fluorescence
(TIRF) and structured illumination microscopy (SIM) to
detect the position of endosomes relative to the plasma
membrane during the uptake of ligands (39). Using this
methodology, we find that sd-rxRNA oligonucleotides in-
ternalize selectively through a pathway similar to that taken
by the EGF receptor, which utilizes endosomes enriched in
the phosphoinositide-binding protein EEA1 (37,40–43). In
addition, we demonstrate that the second step of intracel-
lular localization is saturable, further supporting the no-
tion of potential chemistry-guided endosome sorting. De-
termination of the mechanism of oligonucleotide uptake is
important for enhancing both in vitro and in vivo efficacy.
The recognition that hydrophobic oligonucleotide uptake
involves distinct intracellular endosomal pathways and is
saturable will aid in the development of rational strategies
to enhance the potency and utility of RNAi-based thera-
peutics.
MATERIALS AND METHODS
Reagents
Polyclonal EEA1 antibody was produced in chickens by in-
jecting N-terminal 6-HIS fusion protein of human EEA1
residues 32–218. Polyclonal RBSN antibody was pro-
duced in rabbits by injecting residues 137–784 of human
RBSN. Unconjugated and DyLight-649 conjugated human
transferrin were obtained from Jackson Immunochemicals.
FM4-64 (T3166), Alexa Fluor-labeled epidermal growth
factor (E13345, E35351) and Alexa Fluor-labeled transfer-
rin (T13342, T13342) were obtained from Life Technolo-
gies.
Cell culture and transfection
COS-7 cells were maintained in DMEM (Invitrogen) sup-
plemented with 100 U/ml penicillin streptomycin (Invit-
rogen), 0.1 mg/ml normocin (InvivoGen) and 10% fetal
bovine serum (Atlanta Biologicals) at 37◦C and 5% CO2.
Cells were seeded at a density of 1 × 105 cells per dish in
35 mm dishes (MatTek P35G-0.170-14-C) and grown for 24
h. For transfections, calcium phosphate was used to trans-
fect 1 g DNA. The cells were then washed with fresh me-
dia after 16 hours and allowed to grow for an additional
24 h. Live cell imaging was done in FluoroBrite DMEM
(Thermo Fisher A1896702) within an environmental cham-
ber to maintain 37◦C, 5% CO2 and 100% humidity.
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TIRF/epifluorescence structured illumination microscope
(TESM) optical system
A custom-built microscope system, TESM, simultaneously
combines total internal reflection fluorescence (TIRF) and
wide-field epifluorescence modes and incorporates struc-
tured illumination microscopy (SIM) in the epi mode for
fast optical sectioning and enhanced spatial resolution.
Further details as well as the TESM acquisition system
is described previously (39). Image stacks acquired with
SIM were 10 m tall with slices spaced 100 nm apart. For
co-localization analysis, dual-labeled image sets were con-
volved with a difference of Gaussians (DOG) filter consist-
ing of (i) a small, two dimensional, Gaussian spot with unit
area (sigma= 150 nm) that acted as a vesiclematched detec-
tor, i.e. an approximation to a near-diffraction limited spot
and (ii) a larger, inverted, two dimensional Gaussian (sigma
= 300 nm) with negative unit area that estimated and sub-
tracted the local background. The Gaussian smoothed im-
ages were visually thresholded (global threshold) to select
for pixels belonging to objects (e.g. vesicles) and eliminate
areas devoid of signal (but containing noise). For each la-
bel, its globally thresholded image was used to generate a
binary image by setting the intensity of all positive value
pixels to one and all other pixels to zero. Co-localization
was determined by two-way or three-way binary image over-
lap among the labels. Co-localization values are reported as
the percent of pixels that are co-localized with a given la-
bel: given a pair of 2D binary images of labels A and B, the
percent co-localization of ‘B with A’ at time t is:
100 ×
∑∑
[A(x, y, t)
x y
×B(x, y, t)]/
∑∑
B(x, y, t)
x y
Additionally, non-specific co-localization was calculated
by rotating one of the channels by 180◦ and re-calculating
the co-localization using the same equation. This allowed
us to determine that co-localization was genuine and not
simply due to excess signal.
Confocal microscopy
Confocal images of sd-rxRNA uptake in HeLa cells were
acquired with a Leica DM IRE2 confocal microscope us-
ing a 63× oil immersion objective. Images were processed
in ImageJ (v1.50d). For sd-rxRNA uptake, total fluores-
cence intensity was measured. For measuring sd-rxRNA in
the perinuclear region, a line was drawn through the longest
part of the cell that intersects the nucleus. sd-rxRNA fluo-
rescence intensity was measured on this line 10 pixels from
the nucleus on both sides. Likewise, plot profiles were also
acquired in ImageJ using the same lines.
DeltaVision OMX v4 blaze microscope
Super-resolution 3D-SIM images were acquired on a
DeltaVision OMX V4 (GE Healthcare) equipped with a
60×/1.42 NA PlanApo oil immersion lens (Olympus), 405,
488, 568 and 642 nm solid state lasers and sCMOS cameras
(pco.edge). Image stacks of 10 m with 0.125 m thick z-
sections and 15 images per optical slice (three angles and
five phases) were acquired using immersion oil with a refrac-
tive index of 1.514. Images were reconstructed usingWiener
filter settings of 0.008 for the 405 channel, 0.006 for the
528 channel, and 0.003 for the 508 and 683 channels. Opti-
cal transfer functions (OTFs) were measured specifically for
each channel with SoftWoRx 6.1.3 (GE Healthcare) to ob-
tain super-resolution images with a 2-fold increase in reso-
lution both axially and laterally. Images from different color
channels were registered using parameters generated from a
gold grid registration slide (GE Healthcare) and SoftWoRx
6.5.2 (GE Healthcare). Volume renderings were generated
in ImageJ v1.50g.
Gene expression analysis
The QuantiGene 2.0 bDNA assay (Affymetrix, QS0011)
was used to perform the PPIB sd-rxRNA dose response.
HeLa cells, resuspended in DMEM with 6% FBS without
antibiotics, were added into each well of a 96-well plate with
a density of 5000 cells/50l per well. sd-rxRNAwas diluted
to 2× final concentration in serum freeOptiMEMand 50l
of compound was added to each well for a final volume of
100 l/well and a final concentration of 3% FBS. The mix-
ture was incubated under standard conditions for 72 h and
then cells were lysed and processed according to the man-
ufacturer’s recommended protocol. Briefly, cells were lysed
in 250 l diluted lysis mixture (1:2 lysis mixture:water) with
0.167 ug/l proteinase K (Affymetrix QS0103) for 30 min
at 55◦C. Cell lysates were mixed thoroughly and 20–80 l of
lysate was added to a bDNA capture plate along with 0–60
additional diluted lysis mixture without proteinase K to fill
up to 80l total volume. Probe sets were diluted as specified
in Affymetrix protocol and 20 l of either human HPRT,
PPIB, EEA1 or RBSN probes (Affymetrix: SA-50339, SA-
10003, SA-13403, SA-21039, respectively) were added to
each well of capture plate to a final volume of 100 l. Lu-
minescence was detected on a Tecan M 1000.
Oligonucleotide synthesis
Supplementary Table S1 lists the species used in this study.
Therapure RNA phosphoramidite monomers were pro-
cured from Thermo Fisher Scientific. Synthesis solid sup-
ports (CPG) attached to the first 3′ residue were obtained
from Prime Synthesis (Aston, PA). Synthechol (cholesterol)
was subjected to multi step synthesis to yield Chol-TEG-
Gly succinate (work was performed at Organix, Woburn,
MA, USA) and loaded onto CPG (conducted by Prime
Synthesis Aston PA). Phosphitylation reagent for 5′ phos-
phorylation was procured from ChemGenes (Wilmington,
MA, USA). All other synthesis reagents and solvents were
obtained from American International Chemicals and used
as such. Other chemicals and solvents for post synthesis
workflow were purchased from Sigma Aldrich and used
without any purification or treatment. Oligonucleotides
were synthesized by RXi Pharmaceuticals or UMass using
standard synthesis protocols.
RNA oligonucleotides were synthesized on a Mermade
12 DNA/RNA Synthesizer (Bioautomation, Plano, Texas)
using standard oligonucleotide phosphoramidite chemistry
starting from the 3′ residue of the oligonucleotide preloaded
onCPG support. Synthesized oligonucleotides were cleaved
from the support and the protecting groups were re-
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moved by the successive treatments of 3:1 aqueous am-
monia:ethanol (65◦C, 2 h) (Sigma, St. Louis, MO, USA)
and triethylamine-trihydrofluoride (DMSO, 70◦C, 40 min)
(Sigma, St. Louis, MO). Crude Oligonucleotides were pre-
cipitated with isopropanol (Fisher Scientific, Pittsburgh,
PA,USA) and centrifuged to obtain a pellet. Crude product
was then purified on GE Akta Purifier UPC100 using ion
exchange chromatography (Source 15Q, 20 mM NaH2PO4
(Fisher Scientific, Pittsburgh, PA), 15% CH3CN (Merck,
Billerica, MA, USA), 1 M NaBr (Sigma, St. Louis, MO),
gradient 20–60% B over 30 column volumes) and fractions
were analyzed by reverse phase ion pair chromatography
on a Shimadzu HPLC. Pure fractions were pooled and de-
salted by Tangental Flow Filtration using Sius PES 3000
MWCO (High Purity New England, Providence, RI, USA)
and evaporated to dryness on GeneVac Personal Evapo-
rator (SP Industries, Warminster, PA, USA). The purity
and molecular weight were determined by HPLC anal-
ysis (Shimadzu Prominence, XBridge OST C18 column,
25 mM hexylammonium acetate-acetonitrile (Sigma, St.
Louis, MO) buffer system, 60◦C) and ESI-MS analysis us-
ing Promass Deconvolution for Xcalibur (Novatia, Mon-
mouth Junction, NJ, USA).
RESULTS
sd-rxRNA quickly internalizes through endocytic pathways
following membrane association
sd-rxRNAs are asymmetric compounds with a short du-
plex region (15 base pairs) and a single-stranded tail which
is typically phosphorothioated (PS). In addition, chemi-
cal modifications are incorporated throughout the com-
pound, including 2′-fluoro and 2′-O-methyl modifications
(providing stabilization and avoidance of PKR response),
and the 3′ end of the passenger strand may be conjugated
to TEG-Cholesterol (Figure 1A). The cholesterol enables
quick membrane association while the single-stranded PS
tail is essential for cellular internalization by a mechanism
similar to that used by conventional antisense oligonu-
cleotides (30,44–45). Both the cholesterol and PS tail are
essential for in vitro activity; without the cholesterol conju-
gate, the oligonucleotide shows very little activity and up-
take in HeLa cells (Supplementary Figure S2). Addition
of Cy3-labeled sd-rxRNA to any cultured cell type shows
quick and efficient internalization (data for COS-7 cells
shown in Figure 1C) and gene silencing (Figure 1B). Com-
pounds are effective in vivo upon local administration in
skin (23), eye (9), and brain (46). The compound targeting
CTGF is now in Phase II clinical trials to prevent or reduce
hypertrophic scar formation following scar revision surgery
(47, https://clinicaltrials.gov/ct2/show/NCT02030275). In-
ternalization in vitro is independent of extracellular fac-
tors, such as LDL and other serum components which shift
dose response curves ∼3-5 fold (data not present), suggest-
ing that sd-rxRNA contains the chemical features required
for cellular association and internalization. Interestingly,
lipoproteins have been implicated in cholesterol modified
delivery in vivo (30–32), indicating that in vivo and in vitro
mechanisms of uptake might be different.
Here, we first visualize the uptake of sd-rxRNA into
COS-7 cells using TESM. Fluorescently-labeled sd-rxRNA
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Figure 1. Structure of sd-rxRNA, gene silencing efficacy, and cellular
internalization. (A) Chemical modifications of sd-rxRNA include 2′-O-
methyl, 2′-fluoro, phosphorothioate linkages, and cholesterol covalently
linked at the 3′ end of the sense strand by a tetraethylene glycol (TEG)
linker. (B) Dose response was performed in HeLa cells using PPIB-
targeting sd-rxRNA (UNT: untreated cells). mRNA levels were measured
by QuantiGene Assay (Affymetrix). (C) COS-7 cells were treated with
250 nM sd-rxRNA-DY547 (red) and visualized by total internal reflection
(TIRF) microscopy (see Supplementary Video 1). Scale bar = 10 m.
targeting MAP4K4 (sd-rxRNA-DY547) (9) was added to
COS-7 cells at 250 nM and uptake was visualized using live
cell TIRF microscopy (see Methods, Figure 1C, Supple-
mentary Video 1). Initial diffuse membrane association is
observed within 15 seconds of oligonucleotide exposure fol-
lowed by the formation of clear, vesicular structures.Within
15 min, a major fraction of fluorescent sd-rxRNA is inter-
nalized with vesicles showing semi-random movement in
the perinuclear space with the nucleus being clearly visi-
ble as oligonucleotide-free (Supplementary Video 1). Sim-
ilar uptake can be observed in the presence and absence of
serum with serum actually inhibiting uptake (Supplemen-
tary Figure S1), indicating that initial membrane associa-
tion is primarily driven by cholesterol hydrophobicity and
direct integration into the membrane or interaction with
membrane components rather than binding to serum pro-
teins followed by internalization. These data are consistent
with previous studies demonstrating that the presence of
serum is inhibitory to hydrophobically modified siRNA ef-
ficacy in vitro (28,29).
Due to their cholesterol moiety, sd-rxRNAs are highly
hydrophobic and efficiently associate with plasma mem-
branes; thus, its subsequent internalization might be medi-
ated by bulk phase pinocytosis. The lipophilic styryl dye,
N-(3-triethylammoniumpropyl)-4-(p-diethylaminophenyl-
hexatrienyl)pyridinium dibromide (FM4-64), has been
extensively used as a vital stain to follow bulk membrane
internalization as well as the formation of endocytic
vesicles (48–53). It is inserted into the outer leaflet of the
plasma membrane, where its interactions with lipids result
in strong fluorescence in the far-red spectrum. COS-7
cells were simultaneously treated with 250 nM sd-rxRNA-
DY547 and 0.5 g/ml FM4-64 and visualized using live
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Figure 2. sd-rxRNA is internalized through a saturable pathway. (A) HeLa
cells were treated with 0.5 M sd-rxRNA-Cy3 and imaged by live con-
focal microscopy. Uptake was quantified by measuring total fluorescence
intensity at specific time points. (B) HeLa cells were either untreated (con-
trol) or pre-incubated with 2 M unlabeled sd-rxRNA for 10 or 60 min.
Cells were then treated with 0.5 M sd-rxRNA-Cy3 and imaged by live
cell confocal microscopy. sd-rxRNA fluorescence intensity was measured
in a region only 10 pixels from the nucleus. (C) Representative images used
for quantification in panels B and D. Blue represents DAPI stain and red
represents Cy3-labeled sd-rxRNA. Scale bar= 10 m. (D) Corresponding
plot profiles of lines drawn through images in panel C. Blue lines repre-
sent DAPI stain intensity and red lines represent Cy3-labeled sd-rxRNA
intensity.
cell TIRF microscopy. Within seconds of addition to the
medium, both sd-rxRNA-DY547 and FM4-64 were both
seen labeling the cell in a diffuse pattern, consistent with
their partitioning into the hydrophobic plasma membrane.
While there is some co-localization, sd-rxRNA also formed
puncta distinct from FM4-64 (Supplementary Figure S3,
Supplementary Video 2). These results suggested that
another pathway might be predominantly contributing to
sd-rxRNA trafficking.
sd-rxRNA cellular internalization, but not membrane bind-
ing, is saturable
When sd-rxRNA is added to cellular media, uptake is al-
most immediate; by 24 h, a small fraction of compounds
present in the media is associated with the cells and contin-
uous exposure does not significantly increase the amount
of internalized compound (Figure 2A). In order to deter-
mine whether this endocytic process is saturable, we ex-
posedHeLa cells to 2Mof unlabeled sd-rxRNA for either
10 or 60 min, chased by the addition of 0.5 M fluores-
cently labeled oligonucleotide. The kinetics of sd-rxRNA-
Cy3 uptake in naı¨ve and pre-treated cells was imaged by
live cell confocal microscopy (Figure 2C). In naive cells,
consistent with data presented in Figure 1 (Supplementary
Video 1), sd-rxRNA-Cy3 internalization could be easily de-
tected within 10 min, with oligonucleotide bound to the
membrane and distributed in the cytoplasm. Conversely,
pre-incubation with unlabeled sd-rxRNA effectively blocks
sd-rxRNA-Cy3 cellular internalization (Figure 2B). By 60
min, both control and pre-treated cells showed a dramatic
increase in uptake, but the control cells were filled with sd-
rxRNA whereas in the pre-treated cells, the majority of sd-
rxRNA localized to the membrane and not in the perinu-
clear region (Figure 2C andD). This effect persisted for sev-
eral hours; however, by 180 min, sd-rxRNA uptake in both
conditions had settled to similar levels, indicating that by
3 h, the factor limiting internalization is recycled back or
resynthesized. Taken together, these results suggest that the
cellular uptake sd-rxRNA is a two-step process: first, associ-
ationwith the plasmamembrane by a lipophilic and/or pro-
tein interaction and second, internalization by a saturable
endocytic mechanism.
sd-rxRNA preferentially traffics with EGF compared to Tf
by live cell TIRF imaging
In order to further investigate the trafficking mechanism of
sd-rxRNA, we compared the cellular uptake with respect to
the classical trafficking markers EGF and Tf, whose traf-
ficking pathways are well-defined and, in general, do not
overlap. EGF goes to late endosomes/lysosomes for degra-
dation, whereas Tf is recycled back to the plasmamembrane
(37,38). To this end, we used sd-rxRNA-Cy3 in conjunc-
tion with Alexa Fluor 647-labeled EGF (EGF-Alexa647)
and Alexa Fluor 488-labeled Tf (Tf-Alexa488). COS-7 cells
were simultaneously treated with 250 nM sd-rxRNA-Cy3, 2
ng/l EGF-Alexa647 and 25 ng/l Tf-Alexa488. After 10
min, the cells were washed with fresh media to remove un-
bound ligand.Uptakewas visualized continuously byTIRF
microscopy (Supplementary Video 3).
As previously reported, EGF-Alexa647 bound to dis-
crete regions of the plasma membrane distributed at the
cell periphery (54) while sd-rxRNA displayed a homoge-
nous distribution on the plasma membrane which intensi-
fied over time (Figure 3A). Over the course of the experi-
ment, sd-rxRNA-Cy3 and EGF-Alexa647 foci were clearly
co-localizing and moving together, likely inside endosomes
(Figure 3B). These results indicate that sd-rxRNA internal-
izes, at least in part, through a trafficking pathway also in-
volved in EGF uptake.
Conversely, Tf-Alexa488 rapidly bound to the plasma
membrane onto variably sized punctate regions due to
the concentration of receptors in clathrin-coated pits and
patches on the plasma membrane (Figure 3A) (55,56). Tf
was subsequently internalized into highly dynamic endo-
cytic structures of different shapes and sizes and accumu-
lated in a compact region near the nucleus known as the
recycling compartment. In contrast, sd-rxRNA-Cy3 ho-
mogenously labeled the plasma membrane and gradually
concentrated over time. This behavior is consistent with a
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Figure 3. sd-rxRNA preferentially associates with EGF compared to Tf
by live cell TIRF. (A) COS-7 cells were simultaneously treated with 250
nM sd-rxRNA-Cy3, 2 ng/l EGF-Alexa647, and 25 ng/l Tf-Alexa488.
After 10 min, the cells were washed with fresh media and imaged by TIRF.
Representative time-lapse images are shown (see Supplementary Video 3).
Scale bar = 10 m. (B) Enlarged images from panel A. Scale bar = 2 m.
non-specific partitioning of sd-rxRNA-Cy3 into the plasma
membrane, likely attributable to the hydrophobic choles-
terol moiety. sd-rxRNA-Cy3 and Tf-Alexa488 could be
seen in distinct vesicular structures, suggesting that the level
of overlap in trafficking pathways is minimal (Figure 3B).
Quantitative analysis of sd-rxRNA co-trafficking with Tf and
EGF shows preferential co-localization with EGF by fixed
cell structured illumination microscopy
While live cell imaging shows clear differences between the
degree of sd-rxRNA co-localization with EGF and Tf, we
next moved to confirm these results using more quantita-
tive methods, allowing evaluation of plurality of cells si-
multaneously, rather than one cell at a time. COS-7 cells
were simultaneously treated with sd-rxRNA-Cy3, 1 ng/l
EGF-Alexa488 and 25 ng/l Tf-Alexa647 and washed with
fresh media at 5 min, allowing simultaneous visualization
of all three ligands. At different time points, cells were
Figure 4. Quantitative analysis of sd-rxRNA co-trafficking with Tf and
EGF shows preferential co-localization with EGF by fixed cell structured
illumination microscopy. (A) COS-7 cells were grown on cover slips and
simultaneously exposed to 25 ng/l Tf-Alexa647, 250 nM sd-rxRNA-
Cy3, and 1 ng/l EGF-Alexa488 at 37◦C and washed at 5 min. Cover
slips were transferred to ice-cold PBS and then immediately fixed in 4%
paraformaldehyde at the specified time points. Images were acquired by
SIM and representative maximum intensity projections of cells fixed at 30
min are shown (see Supplementary Video 4). (B) Co-localization analysis
of panel A is presented as mean ± SEM. Scale bar = 10 m. Dotted line
indicates wash with fresh media (*P < 0.05, **P < 0.01, ***P < 0.001,
two-tailed Student’s t-test).
fixed and optical sectioning images were acquired by SIM.
Co-localization analysis was performed on 500 nm optical
slices and integrated for the whole cell. Non-specific co-
localization was estimated by rotating one channel by 180
degrees and was always below 1% (seeMethods for details),
confirming that observed co-localization is indeed biolog-
ically relevant. For each time point, 10–20 cells were ana-
lyzed and a two-tailed Student’s t-test was performed.
In fixed cells, we again visually observed that sd-rxRNA
preferentially co-localized with EGF compared to Tf (Fig-
ure 4A, yellow dots). Prior to 15 min, the majority of sd-
rxRNA was associated with the plasma membrane out-
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side the cell and the percent of sd-rxRNA co-localization
with either EGF or Tf remained under 2%. However, by
20 min, the percent co-localization of sd-rxRNA with EGF
increased to ∼14%. By 30 min, sd-rxRNA was clearly co-
localizing preferentially with EGF compared to Tf as seen
in a 3D projection of a cell (Supplementary Video 4). This
trend continued and peaked at ∼24% by 45 min before
falling back to ∼10% at 60 min. Conversely, the percent co-
localization of sd-rxRNA with Tf increased to only ∼4%
between 20 and 45 min. This significant difference persisted
for all time points measured at 20 min and later (Figure
4B). Together, these results quantitatively confirm the ini-
tial observation from live cell imaging, suggesting that ama-
jor fraction of sd-rxRNA preferentially shares a trafficking
pathway utilized for EGF internalization.
sd-rxRNA preferentially associates with EEA1- but not
RBSN-enriched endosomes
In order to further dissect the sd-rxRNA trafficking path-
way, we looked at two putative endosomal markers which
have been implicated in EGF and Tf trafficking. Recent
data suggests that EGF and Tf sorting occurs through en-
dosomes enriched in early endosome antigen 1 (EEA1) and
rabenosyn-5 (RBSN) (57), respectively. Consistently, EEA1
knockdown results in EGF missorting (37) and RBSN
knockdown results in Tf missorting (39). To fluorescently
tag these endosomal markers, COS-7 cells were transiently
transfected with either GFP-EEA1 or GFP-RBSN fusion
expressing plasmids (39).We first confirmed that there is lit-
tle degree of co-localization between Tf and EGF (Supple-
mentary Figure S4). Furthermore, EGF preferentially co-
localizes with EEA1 and Tf preferentially co-localizes with
RBSN (Supplementary Figure S5). Use of these cells ex-
pressing GFP fusions of endosomal markers allows evalua-
tion of sd-rxRNA uptake in a non-perturbed state to en-
sure that observed preferential co-localization with EGF
was not impacted by the initiation of EGF or Tf. The cells
expressing GFP-EEA1 and GFP-RBSN (Figure 5) were
treated with 250 nM sd-rxRNA-Cy3 and co-localization
analysis was performed as described above (Figure 5A, 5B).
sd-rxRNA showed a pattern of co-localization with EEA1-
enriched endosomes similar to that of EGF, with levels
steadily increasing to ∼15% after 15 min and peaking at
∼19% from 30 to 45 min before dropping to ∼6% at 60
min. Conversely, the percent co-localization of sd-rxRNA
with GFP-RBSN was low (Figure 5C). Furthermore, when
COS-7 cells were continuously incubated with sd-rxRNA
for 22 hours, we again observed the same pattern of pref-
erential co-localization with EEA1 compared to RBSN
(Supplementary Figure S6). These results further support
preferential trafficking of hydrophobic siRNAs through
EGF/EEA1 involved pathways using an intracellular ex-
pressed marker system.
To test the functional relevance of these pathways, HeLa
cells were first transfected with siRNAs targeting either
EEA1, RBSN, or a non-targeting control (NTC) using
RNAiMAX and then a dose response using sd-rxRNA tar-
geting PPIB was performed. However, all transfected cells
showed slightly enhanced sd-rxRNA silencing efficacy com-
pared to untransfected cells (data not shown). Unfortu-
Figure 5. sd-rxRNA preferentially associates with EEA1- but not RBSN-
enriched endosomes. COS-7 cells were grown on cover slips and trans-
fected with either (A) GFP-EEA1 or (B) GFP-RBSN plasmids. All cells
were grown on cover slips, kept at 37◦C, treated with 250 nM sd-rxRNA-
Cy3 and washed with fresh media at 5 min. At the specified time points,
cover slips were transferred to ice-cold PBS and then immediately fixed
in 4% paraformaldehyde. Images were acquired by SIM and representa-
tive maximum intensity projections of cells fixed at 30 min are shown. (C)
Co-localization analysis of panels A and B are presented as mean ± SEM.
Scale bar = 10 m (inset scale bar = 500 nm). Dotted line indicates wash
with fresh media (*P < 0.05, **P < 0.01, two-tailed Student’s t-test).
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nately, it is difficult to make a conclusion based on these
results since any pre-treatment (transfection, electropora-
tion, etc.) modifies or stresses the membrane composition,
potentially altering the self-delivery pathway.
DISCUSSION
Recently, significant effort in the siRNA field has focused
on determining the mechanisms and pathways of oligonu-
cleotide cellular uptake (58,59). It has been shown that
when siRNA is delivered with LNPs in HeLa cells, only
∼100 loaded RISCs are required to achieve 50% gene si-
lencing, which is significantly less than 1% of the total in-
tracellular siRNA (11). This paradox of highly inefficient
delivery to the site of action has raised the question of
whether the precise mechanism by which RNAi-inducing
compounds are delivered to cells plays a role in their silenc-
ing activity.Moreover, it is not clearwhether all of theRNAi
compounds taken up by cells can functionally engage with
RISC, or whether distinct productive and non-productive
uptake pathways exist. This information, and the elucida-
tion of which pathways are productive, is required to sys-
tematically develop approaches to improve therapeutic po-
tential. In addition, knowledge of intracellular pathways in-
volved in silencing by RNAi oligonucleotides may inform
on natural biological mechanisms of silencing.
Cholesterol conjugation has long been known to promote
association with the cellular membrane, even with single-
stranded oligonucleotides (60,61). Here, we study the in-
ternalization of sd-rxRNAs, hydrophobically modified siR-
NAs, which efficiently enter cells and tissues without re-
quirement for the delivery vehicle. We use EGF and Tf as
trafficking markers to get a better understanding of the in-
tracellular fate of the oligonucleotide and mechanisms in-
volved in the uptake. We observed preferential sd-rxRNA
association with EGF trafficking which suggests the in-
volvement of specific cell surface receptors. EGF internal-
ization is dependent on rapid phosphorylation and ubiqui-
tination of high affinity receptors. At low EGF concentra-
tions, few receptors internalize, and their uptake takes place
through clathrin-coated pits. However, at higher concentra-
tions, most receptors internalize through macropinocytosis
(62,63).
Hydrophobic siRNA internalization is very quick and
saturable. Pre-incubation of cells just for ten minutes with
non-labeled compound of identical chemical composition
chased with the labeled oligonucleotides effectively blocks
labeled compound internalization without any significant
effect on membrane binding. This supports a two-step
mechanism with membrane binding and cellular uptake
being functionally independent events. Membrane binding
is likely driven by overall hydrophobicity of the oligonu-
cleotide and cholesterol ability to intercalate into the mem-
branes, consistent with initial diffuse, non-saturable and re-
versible membrane staining. Then, the compounds are in-
ternalized through a hypothetical receptor interaction and
significantly overlap with EGF-containing endosomes. The
second step is fully saturable within minutes. Three to six
hours is required for the machinery involved in internaliza-
tion to be recycled or resynthesized. This observation could
potentially inform on a better oligonucleotide dosing regi-
men in vivo.
The study of the cellular uptake mechanisms of oligonu-
cleotides is complicated by their requirement for endocyto-
sis to enter the cell and need to exit from these organelles to
gain further access into the cytoplasmic space. The endo-
cytic pathway in mammalian cells is highly complex; cargo
may be internalized from the plasma membrane by several
different mechanisms, and following internalization enter a
system of endosomes, which are numerous, dynamic and
highly heterogeneous in size, shape, composition and lo-
cation (35,64–70). Thus, defining the pathways of oligonu-
cleotide entry requires techniques that can monitor the
compound of interest relative to the plasma membrane and
distinct endosome classes with sufficient temporal and spa-
tial resolution. TIRF microscopy provides a high resolu-
tion, sensitive method to monitor the localization of flu-
orophores in the vicinity of the plasma membrane, where
all initial events of endocytosis take place. The spatial res-
olution of TIRF is further enhanced by information re-
garding the exact brightness of visible objects obtained by
SIM. Using these optical approaches, visualization of two
extensively studied systems––Tf and its receptor (TfR), and
EGF and its receptor (EGFR) (40,71–73)––has revealed
that these ligands follow distinct trafficking pathways im-
mediately after internalization (37,38).
The mechanisms by which internalized sd-rxRNA
achieves target silencingmust involve its interactionwith cy-
toplasmic RISC. Previous reports suggest that components
of RISC are associated with multi-vesicular body mem-
branes, and that depletion of multi-vesicular bodies impairs
silencing activity (74,75). EEA1 is associated with endo-
somes that contain cargo destined for lysosomes, which in
turn involves the formation of multi-vesicular bodies (76).
This interpretation is supported by studies in which deple-
tion of hepatocyte growth factor-regulated tyrosine kinase
substrate (Hrs) (77), which is involved in multi-vesicular
body formation, results in both impaired EGFR degrada-
tion (78) and diminishedmiRNA silencing (75). Conversely,
knocking down members of the ESCRT-I complex has also
been shown to increase both in vitro and in vivo efficacy of
anti-miR compounds (miRNA inhibitors), although its role
in the context of antisense oligonucleotide or siRNA deliv-
ery is still unclear and warrants further study.
Once internalized, EGF receptors are associated with en-
dosomes characterized by the presence of EEA1 (37,41–
43,79–80). The co-localization of sd-rxRNA with EGF is
consistent with direct RNA-receptor interactions. RNA
binding to receptors has been reported, for example, double
stranded RNA 20-30-mers bind to pattern recognition re-
ceptors (81,82).Whether these receptors are activated by sd-
rxRNA, how they are internalized and the degree of over-
lap with cholesterol trafficking is a subject of further eval-
uation. The preferential internalization of oligonucleotides
into specific endosomesmay be relevant for its biological ac-
tivity, as different endosome classes are associated with dif-
ferent fates; Tf internalization, which involves endosomes
characterized by the presence of RBSN (39,83), is followed
by recycling to the plasmamembrane, while the internaliza-
tion of EGF into endosomes containing EEA1 is followed
by lysosomal degradation (37,42,80). In fact, it has been
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Figure 6. Proposed model of sd-rxRNA internalization and trafficking. EGF traffics through EEA1-enriched endosomes and is sent to the lysosome for
degradation while Tf traffics through RBSN-enriched endosomes and is recycled back to the plasma membrane. A fraction of internalized sd-rxRNA
preferentially traffics through EEA1-enriched endosomes, similar to EGF. In order to achieve target silencing, sd-rxRNAmust undergo endosomal escape
in order to reach the cytoplasm where the components of RISC, such as Argonaute 2 (Ago2), are located; however, this mechanism is still not known.
shown that ∼70% of internalized siRNAs are effluxed out
of the cell by a Niemann-Pick type 1 (NPC1) pathway, sug-
gesting that efficacy could be improved by escaping these re-
cycling pathways (26). Furthermore, another recent paper
suggested that endosomal escape occurs at a very low fre-
quency and only from a specific subset of endosomes (13).
However, both of these studies used LNP-mediated siRNA
delivery, so how relevant these observations may be for self-
delivering hydrophobically modified siRNAs remain to be
seen.
In summary, we show that the internalization of sd-
rxRNAs, a class of hydrophobically modified siRNAs, is a
quick, two-step process, involving membrane binding and
saturable preferential sorting into an EGF-EEA1-like path-
way (Figure 6). However, it is important to note that ac-
cumulation of sd-rxRNA in EEA1-containing endosomes
does not imply that this is a productive pathway and thus
a preferable uptake mechanism for their silencing activity.
Rather, this is a method to visualize the internalization and
trafficking of these molecules and can be used to further in-
vestigate other conjugates and pathways.
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